SOLIGENIX INC (SNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.33-4.99%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SNGX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -90.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 84.1% |
Growth built into the price is above our model estimate.
The price assumes 174.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
SNGX — debt issuance
Dated 2026-09-21
Other Events. On June 26, 2026, Soligenix, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement, dated January 23, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC, by an additional aggregate amount of $2,500,000. The Company previously sold approximately $6,234,000 of shares…
Why it matters: Soligenix received a Nasdaq notice for trading below $1.00. An update will show whether the company has fixed this listing issue.
Watch forA company filing or Nasdaq notice says SNGX met the $1.00 minimum bid rule for the required time.
Also watch forA filing says SNGX did not regain compliance by the deadline, or Nasdaq starts delisting steps.
Why it matters: Soligenix increased its share offering and had already sold about $6.234 million of shares. More sales can add cash but dilute current holders.
Worry ifA new filing reports more shares sold under the Sales Agreement. Or it raises the $2.5 million added offering limit.
Less concerning ifA filing says the Sales Agreement is closed or its limit is not increased, with no new shares sold.
Why it matters: FLASH 2 stopped after its interim review found the trial was futile. New data could clarify if any patient group may still benefit.
Watch forSoligenix reports a patient group with a clear treatment signal and says it will seek FDA or EMA talks.
Also watch forSoligenix says its data review found no useful group of patients. Or it ends HyBryte work with no follow-up plan.
Why it matters: Management said it would weigh strategic options with about $5.9 million in cash. A clear plan will show which path it is pursuing.
Watch forSoligenix names a merger partner. Or it gives a funded timeline to advance dusquetide for Behçet's disease.
Also watch forSoligenix reports no deal or funded plan for dusquetide. It raises more capital to cover operations.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$151 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $699 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,302 loss on $10,000 · 83.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.